MDT news sentiment

Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar

Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on the ratio chart against the over the past two months. Continue Reading

Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall

This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator

Versa Vascular Appoints Bill Shields as Chief Executive Officer

Company Expands Series C Financing to $42M SANTA CRUZ, Calif., August 11, 2026--(BUSINESS WIRE)--Versa Vascular, Inc., a pioneering medical device company dedicated to transforming tricuspid valve disease treatment, announced the appointment of Bill Shields as Chief Executive Officer. Former Versa CEO David Hovda is retiring and will remain an advisor to the company. Shields spent the last 15 years with Medtronic's structural heart franchise, most recently as Vice President and General Manager of its Transcatheter Mitral and Tricuspid Therapies division, where he spent seven years leading prod

Pulsed Field Ablation Global Market Report 2026 Now Available - Profiles Boston Scientific, Medtronic, Biosense Webster, and 15 Other Players

Company Logo Pulsed Field Ablation MarketPulsed Field Ablation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players - Trends and Forecast till 2035" has been added to ResearchAndMarkets.com's offering. The global pulsed field ablation market is projected to expand from approximately USD 3.2 billion in 2026 to USD 14.6 billion by 2035, representing a compound annual growth rate of 18.4% during the forecast period. Rising atr

Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know

In the latest close session, Medtronic (MDT) was up +2.58% at $89.41. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq lost 0.32%. The medical device company's stock has climbed by 3.92% in the past month, exceeding the Medical sector's loss of 0.38% and the S&P 500's gain of 3.42%. The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on September 1, 2026. On that day, Medtronic is projected to report earnings of $1.39 per share, which wo

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Holdings, Inc. The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met. Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand. Company to host R&D Day on November

Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?

Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic › Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there

Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech

Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 stocks we like better than Intuitive Surgical › Intuitive Surgical(NASDAQ: ISRG) can be hard to own because the stock is prone to deep drawdowns. It is in a drawdown right now, with the stock down roughly 40% from its early 2025 high. Even after that drop, the price-to-earnings ratio remains lofty at 42x. Th

Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Medtronic (NYSE:MDT) receives expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmia treatment. The Sphere-9 catheter also holds a Breakthrough Device Designation from the U.S. FDA, which highlights its potential clinical impact. This broader regulatory progress could influence Medtronic's position in cardiac arrhythmia care across international markets. As cardiac care technology evolves and Medtronic advances

Canandaigua National Bank & Trust Co. Takes $926,000 Position in Medtronic PLC $MDT

Medtronic (MDT) Laps the Stock Market: Here's Why

Intuitive Surgical (ISRG) vs. Medtronic (MDT): Which MedTech Stock Looks Better Positioned for Growth?